Refusal, Suspension and Cancellation: Fourteen Grounds in Nicaragua

1. Key takeaways

Chapter 10 of NTON 24001:2023 lists fourteen grounds on which a sanitary registration may be refused, suspended or cancelled. They fall into four groups: untrue information in items 1 to 3, loss of the commercial operator’s standing in item 4, product quality and safety in items 5 to 10, and failure to comply with import or testing obligations after registration in items 11 to 13. Item 14 covers cancellation at the request of the holder. Item 9 carries a NOTA explaining that the response depends on the risk involved: the registration may be suspended temporarily, or cancelled where the risk-benefit balance inclines towards risk.

• Fourteen grounds are grouped by cause: information, operator standing, product safety and post-registration compliance.
• A distributor’s or importer’s lapsed licence can bring down the product registration, which makes partner monitoring a registration issue.
• Failure to complete a correction within the deadline is itself a ground for refusal.
• International alerts count only where they are regarded as serious or of high impact.
• Several grounds attach to conduct after grant, including never importing the product.
• Cancellation at the holder’s request is a different route from cancellation for breach.

2. Legal basis

The table reproduces the fourteen grounds as grouped in Chapter 10, together with the two NOTAs that qualify the response to safety alerts and the retesting of failed batches.

3. Expert insights

The first point is item 4, which links the licence status of the distributor directly to the product registration. It is the only ground among the fourteen in which the compliance position of another party, the distributor or importer, can defeat the registration of the product. It is also the risk most likely to spill over from a commercial relationship into a regulatory event, because a partner’s expired licence is not something the registration holder controls day to day.

The second point is item 5. Failure to satisfy one hundred per cent of the requirements within the prescribed period is the formal landing place for a missed correction deadline. It connects the correction periods in Chapter 7, articles 3 and 5 with refusal: a delay does not merely void the current application, it also constitutes a ground for refusal.

The third point is the pairing of items 6 and 9. Item 9 names the issuing bodies: OMS, OPS, ECRI, FDA and others. Both provisions are limited by the requirement that the alert be regarded as serious or of high impact, so not every alert triggers action, and the authority is expected to analyse the cause before any measure is taken.

The fourth point is the NOTA to item 9, which introduces temporary suspension as an intermediate response: “se podrá suspender temporalmente mientras se resuelve la situación de peligro, o se cancela si se determina que el riesgo beneficio… está inclinado al riesgo”. Cancellation is not the only outcome, and the intensity of the measure is tied to the risk.

The fifth point is that items 11 to 13 all address post-registration compliance with import or testing duties: failure to request analysis of a new batch within the deadline in item 11, failure of the second batch in item 12, and failure to import the product during the validity period in order to complete the first-import inspection in item 13. Item 13 deserves particular attention, because a registration that is obtained and then left unused can be cancelled.

The sixth point is the NOTA to item 12, which provides a technical remedy: an applicant who disputes the test result may ask the quality control laboratory directorate to retest, and may be accompanied by the expert designated for the analysis, “que incluya acompañamiento del experto designado para la realización del análisis”. This is the only one of the fourteen grounds that expressly provides a channel for challenge.

The seventh point is item 14. Cancellation at the request of the holder is different in character from cancellation for breach. A company leaving the Nicaraguan market should use this route rather than allowing the registration to lapse.

4. Practical recommendations

• Include the licence status of distributors and importers in the monitoring register for the product registration, as required by Chapter 10, item 4.
• Manage correction deadlines as hard cut-offs: a delay both voids the application and constitutes a ground for refusal under item 5.
• Monitor international safety alerts from OMS, OPS, ECRI and FDA, and assess whether an alert touching a registered product is serious or of high impact, in line with items 6 and 9.
• After grant, complete the first import and the first-import inspection as planned so as not to fall within item 13.
• Where a batch fails testing, assess a retest request with expert accompaniment under the NOTA to item 12.
• Leave the market through the holder-requested cancellation in item 14 rather than leaving a registration dormant.

5. Verification checklist

• □ Distributor and importer licence status is part of the product registration monitoring register.
• □ Correction deadlines are managed as hard cut-offs, with item 5 recognised as the consequence of delay.
• □ Monitoring of international safety alerts from OMS, OPS, ECRI and FDA is in place.
• □ The first import and first-import inspection are scheduled so as to avoid item 13.
• □ A retest under the NOTA to item 12 has been assessed where a batch fails.
• □ Any market exit plan uses the holder-requested cancellation in item 14.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com